Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

  • Ana De Jesus-Acosta
  • , Elizabeth A. Sugar
  • , Peter J. O’Dwyer
  • , Ramesh K. Ramanathan
  • , Daniel D. Von Hoff
  • , Zeshaan Rasheed
  • , Lei Zheng
  • , Asma Begum
  • , Robert Anders
  • , Anirban Maitra
  • , Florencia McAllister
  • , N. V. Rajeshkumar
  • , Shinichi Yabuuchi
  • , Roeland F. de Wilde
  • , Bhavina Batukbhai
  • , Ismet Sahin
  • , Daniel A. Laheru

Research output: Contribution to journal › Article › peer-review

129 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry